Lukas Flatz
Lukas Flatz
University of Tübingen (Medical Faculty)
Adresse e-mail validée de - Page d'accueil
Citée par
Citée par
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum, AJ Templeton, ...
Lung cancer 111, 176-181, 2017
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
O Demaria, A De Gassart, S Coso, N Gestermann, J Di Domizio, L Flatz, ...
Proceedings of the National Academy of Sciences 112 (50), 15408-15413, 2015
Interferons direct Th2 cell reprogramming to generate a stable GATA-3+ T-bet+ cell subset with combined Th2 and Th1 cell functions
AN Hegazy, M Peine, C Helmstetter, I Panse, A Fröhlich, A Bergthaler, ...
Immunity 32 (1), 116-128, 2010
Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer
F Berner, D Bomze, S Diem, OH Ali, M Fässler, S Ring, R Niederer, ...
JAMA oncology 5 (7), 1043-1047, 2019
Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
C Gil-Cruz, C Perez-Shibayama, A De Martin, F Ronchi, K Van Der Borght, ...
Science 366 (6467), 881-886, 2019
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA
L Flatz, A Bergthaler, JC de la Torre, DD Pinschewer
Proceedings of the National Academy of Sciences 103 (12), 4663-4668, 2006
Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection
R Sommerstein, L Flatz, MM Remy, P Malinge, G Magistrelli, N Fischer, ...
PLoS pathogens 11 (11), e1005276, 2015
Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses
AA Navarini, M Recher, KS Lang, P Georgiev, S Meury, A Bergthaler, ...
Proceedings of the National Academy of Sciences 103 (42), 15535-15539, 2006
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity
L Flatz, AN Hegazy, A Bergthaler, A Verschoor, C Claus, M Fernandez, ...
Nature medicine 16 (3), 339-345, 2010
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
OH Ali, F Berner, D Bomze, M Fässler, S Diem, A Cozzio, M Jörger, ...
European Journal of Cancer 107, 8-14, 2019
Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis
P Cottagnoud, M Pfister, F Acosta, M Cottagnoud, L Flatz, F Kühn, ...
Antimicrobial agents and chemotherapy 48 (10), 3928-3933, 2004
T cell-dependence of Lassa fever pathogenesis
L Flatz, T Rieger, D Merkler, A Bergthaler, T Regen, M Schedensack, ...
PLoS pathogens 6 (3), e1000836, 2010
Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression
A Bergthaler, L Flatz, AN Hegazy, S Johnson, E Horvath, M Löhning, ...
Proceedings of the National Academy of Sciences 107 (50), 21641-21646, 2010
Impaired antibody response causes persistence of prototypic T cell–contained virus
A Bergthaler, L Flatz, A Verschoor, AN Hegazy, M Holdener, K Fink, ...
PLoS biology 7 (4), e1000080, 2009
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
O Hasan Ali, S Diem, E Markert, W Jochum, K Kerl, LE French, ...
Oncoimmunology 5 (11), e1231292, 2016
Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines
L Flatz, R Roychoudhuri, M Honda, A Filali-Mouhim, JP Goulet, N Kettaf, ...
Proceedings of the National Academy of Sciences 108 (14), 5724-5729, 2011
Severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies
O Hasan Ali, D Bomze, L Risch, SD Brugger, M Paprotny, M Weber, ...
Clinical infectious diseases 73 (9), e2869-e2874, 2021
Association between immune-related adverse events during anti–PD-1 therapy and tumor mutational burden
D Bomze, OH Ali, A Bate, L Flatz
JAMA oncology 5 (11), 1633-1635, 2019
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
S Schmid, S Diem, Q Li, M Krapf, L Flatz, S Leschka, L Desbiolles, ...
Cancer Immunology, Immunotherapy 67, 1825-1832, 2018
CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells
M Braun, AR Aguilera, A Sundarrajan, D Corvino, K Stannard, S Krumeich, ...
Immunity 53 (4), 805-823. e15, 2020
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20